Vyome vs Serina Therapeutics
HIND and SER side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HIND and SER compare
Serina Therapeutics is the larger company, worth 3.3 times as much as Vyome ($36.3M against $11.0M).
Serina Therapeutics scores higher on the StockData Score (2 against 1 for Vyome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HIND | SER |
|---|---|---|
| Size and price | ||
| Market cap | $11.0M | $36.3M |
| Share price | $1.57 | $1.43 |
| Change, 1 year | −71.1% | −63.4% |
| Change, 5 years | −100.0% | 81.0% |
| Beta (5Y) | 1.56 | −1.09 |
| Employees | 18 | 16 |
| StockData Score | ||
| Total score | 1 | 2 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 84.9× | – |
| FCF yield | – | −58.4% |
| Growth | ||
| Revenue growth (TTM) | −67.1% | – |
| Revenue growth, 5Y average | −51.0% | −18.5% (better) |
| Profitability | ||
| Gross margin | 52.7% | – |
| Operating margin | −9190% | – |
| Net margin | −8717% | – |
| Return on equity | −194% (better) | −1175% |
| Return on invested capital | −173% | – |
| Financial health | ||
| Interest coverage | −285.8× | – |
| Current ratio | 4.37 | 6.65 (better) |
| Altman Z-score | −13.52 | −0.10 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | 38.9% | – |
| Shareholder yield | 38.9% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 2.0% | 5.5% |
| Held by insiders | 6.8% | 49.7% |
| Insider net buying, 12 months | – | −$232K |
| Short interest, % of float | 0.28% | 0.37% |
Go deeper
- HIND stock overview
- HIND income statement
- HIND valuation and score
- SER stock overview
- SER income statement
- SER valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.